Novel Oral Anticoagulants Versus Warfarin Therapy at Various Levels of Anticoagulation Control in Atrial Fibrillation—A Cost-Effectiveness Analysis
Atrial Fibrillation Monday, October 21st, 2013Journal of General Internal Medicine: October 2013
The decision as to whether to use more expensive novel oral anticoagulants (NOACs) or invest resources for quality improvement of warfarin therapy requires input from both clinical and economic analyses.
OBJECTIVE
Cost-effectiveness of NOACs compared to warfarin therapy at various levels of patient-time in therapeutic range (TTR) in patients with atrial fibrillation was examined, from the healthcare provider’s perspective.
DESIGN, SUBJECTS AND INTERVENTION
A Markov model was used to compare life-long economic and treatment outcomes of warfarin and NOACs in a hypothetical cohort of 65-year-old atrial fibrillation patients with CHADS2 scores of 2 or above. Model inputs were derived from clinical trials published in the literature.
MAIN MEASURES
The outcome measure was incremental cost per quality-adjusted life-year (QALY) gained (ICER). Read more
